ReviewPublic health weekly report2026
U.S. Public Health Policy Shifts Under the Second Trump Administration and Implications for the Republic of Korea's Health Security.
Review in Public health weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This report evaluates the U.S. public health policy shifts enacted by the 2025 Trump administration and assesses their implications for global health cooperation, evidence-based policymaking, and the Republic of Korea's health security strategy. Methods: This study employed a narrative review and policy analysis based on documents published between January 2025 and May 2026. Data were collected from official U.S. federal agency sources and major media outlets using specific search terms, including "Trump administration" and "public health policy." After screening for policy relevance and reliability, the reviewed literature was synthesized and qualitatively analyzed into four main topics: agency reorganization and budget cuts, immunization policy adjustments, data-driven research environments, and global health cooperation. Results: To improve efficiency and realign priorities, the U.S. federal government restructured public health governance by streamlining U.S. Department of Health and Human Services agencies from 28 to 15 and reducing staff. Immunization policy shifted toward emphasizing individual choice, reducing the number of routine recommended vaccines from 17 to 11 by excluding rotavirus, hepatitis A and B, meningococcal, coronavirus disease 2019, and influenza vaccines. Multilateral cooperation also declined as the Centers for Disease Control and Prevention decentralized data management, the U.S. withdrew from the World Health Organization, and the United States Agency for International Development was dissolved, shifting the focus toward bilateral memoranda of understanding. However, these swift transformations triggered sharp institutional resistance, including judicial injunctions, government shutdowns, and state-level policy fragmentation. Conclusions: Alterations to these frameworks and guidelines may reduce the predictability of global infectious disease surveillance and cooperation. Consequently, the Korea Disease Control and Prevention Agency must enhance independent global surveillance, develop science-based communication to sustain vaccine confidence, and diversify multi- and bilateral cooperation networks to keep pace with evolving global health dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.